Once it was fashionable for a patient with severe eczema or psoriasis to be coated with a corticosteroid and then slipped into a polyethylene suit. Many cleared quickly, but some did not escape scot free. Staphylococci liked to multiply under the polyethylene; ugly stretch marks snaked their way across the flexures; and corticosteroids could be forced through the skin in damaging amounts. Diluted creams became contaminated with pseudomonas and themselves caused further sepsis.' Most tiresome of all was the way that psoriasis sometimes surged back, worse than before, when the occlusion was stopped.
Such suits lie dusty in their boxes now but they had done no more than magnify the known effects of topical corticosteroids-both good and bad. Stronger preparations may now achieve the same result without occlusion, and Murphy's law ofcussedness applies to them-as it does to life as a whole. Those which deal best with the rashes will also cause the most side effects. Some patients have been so frightened by vague rumours about these effects that they will not use topical corticosteroids at all, exposing themselves or their children to much discomfort. Some doctors are so unworried by side effects that they hand out prescriptions that are too lavish or too strong. The Glasgow DUMP campaign showed how full some bathroom cupboards may become.2 A sensible balance is needed, and this may usually be achieved by following some simple ground rules.
Firstly, pick the right disease to treat. Eczema of various types is the main target. The proportion of beds in skin departments occupied by patients with eczema fell after topical corticosteroids were introduced': more could be managed as outpatients, and the empty beds were snapped up by patients with psoriasis, which is less responsive to steroids and often better treated with tar, dithranol, or ultraviolet light. For contact eczema, however, the better treatment is based on avoidance of the causative allergen or irritant rather than just on damping down the inflammatory response. Fungal infections may look very like eczema but will take up strange forms if wrongly treated with corticosteroids. 4 Secondly, accept that special rules apply to the face. Here skin atrophy, skin addiction, and rebound flares will result from the use of the more potent preparations. Sneddon described the unpleasant behaviour ofrosacea, in particular. His findings, rightly, are widely known now-and beacon like "corticosteroid facies" no longer peer out of every bus queue. These problems may largely be avoided by sticking to simple hydrocortisone (O 5% or 1 -0%). Stronger preparations are occasionally needed-for example, in discoid lupus erythematosus-but then the general practitioner may be wise to shelter under the wing of a dermatologist.
Next, select preparations of the right strength. Pecking orders for potency are given both in the British National Formulary and in MIMS-but they are not graven on tablets of stone. Some might quibble, for example, about fluocinolone acetonide, even at 000625%, being put into the British National Formulary's "mild potency" group, of which 1% hydrocortisone is the prototype. Few dermatologists would like to see it used on the face. The safest rule is to use the lowest potency which will achieve your purpose, though some like to start with a very short spell on a more potent preparation before dropping to a weaker one. We should be "modestly ashamed of producing atrophy by using a steroid too strong for too long."6 At times, however, some degree of atrophy may have to be a reasonable price to pay for control of incapacitating eczema.
Be wary when prescribing for children. Atherton (from the Hospital for Sick Children, Great Ormond Street) believes that in infants nothing stronger than 1% hydrocortisone should be used at any site and that only mild or moderately potent preparations should be used between the ages of 1 and 5 years.7 Potent preparations may be needed briefly for older children. The judicious use of emollients and bland preparations will help to cut down the quantity of topical corticosteroid which is needed to control the eczema. 
Home nebulisers for airflow limitation
The respiratory drugs that may be given by nebuliser include not only the 1B sympathomimetic agonists and anticholinergics but also disodium cromoglycate,' surface active corticosteroids,2 mucolytic agents,3 anaesthetics,4 and antibiotics. 5 The past four years have seen a rapid growth in the use of domiciliary nebulisers for the administration of bronchodilators. Purchase of a nebuliser unit and air compressor should be approved by a doctor, but some patients have bought them on their own initiative.
Nebulisers have become popular for two reasons. Firstly, they provide a convenient method for giving high doses of bronchodilators, and, secondly, they do not require the same "hand-lung" coordination as a conventional pressurised inhaler. A high dose of 1 agonist (or other bronchodilator) may be delivered to the patient-indeed, the initial quantity of drug placed in the nebuliser is some 25-50 times higher than a conventional dose from a pressurised inhaler. The actual percentage of the dose which enters the airways (10-15%) is similar with both devices.8
In most patients with mild to moderate asthma near maximal bronchodilatation may be achieved with conventional doses of a ,1 agonist delivered from a pressurised inhaler.9 An increase in dosage may result in side effects such as tremor and tachycardia,"°and nebulisers bring such patients no benefit. Other patients, however, do benefit from regular nebulised treatment: these include those unable to use the pressurised inhaler or its various modifications-for example, the very young"-and those with severe chronic airflow limitation who have been shown to benefit from higher than the usual recommended doses of inhaled 1 agonists.'2'7 In such patients there is often a dose response relation to both f3 agonists 1416 and ipratropium bromide.'8 Uncontrolled studies have shown that regular inhaled high dose nebulised 3 agonists may improve lung function"5 '7 and provide symptomatic relief in some patients with chronic airflow limitation.'2 13 IS 17 This may allow a reduction in the dose of other potentially toxic drugs such as oral corticosteroids. 12 Satisfactory double blind prospective trials of high dose bronchodilator treatment have not, however, been published.
The other use of nebulised bronchodilators is as occasional treatment in acute episodes of asthma where conventional treatment has failed.'9 Once again this benefit is almost certainly related to the quantity of drug delivered to the airways rather than the method of delivery. In chronic airflow limitation high dose treatment by metered dose inhaler,20 Rotahaler,'6 tube spacer,'5 or Nebuhaler2' is as efficient as by nebuliser, and bronchodilator delivery by Nebuhaler compares well with nebuliser treatment in acute asthma.22
The widespread use of domiciliary nebulisers has led to concern by physicians over three factors. Firstly, a patient with acute asthma might be tempted to "rely" on his nebuliser, repeating administrations over a short period of time during severe asthma and delaying, perhaps fatally, his decision to call for further help. Some clinicians fear a repeat of the 1960s epidemic of deaths from asthma, which may have been linked with inappropriate reliance on inhalers.22 The explanations offered for the recent increase in deaths in New Zealand include overreliance on home nebulisers, late referral, and underuse of corticosteroids.2324 The second concern is that high doses of f adrenoceptor agonists might be toxic. Overdosage of salbutamol in healthy people appears to present remarkably few problems,25 though hypokalaemia may occur.26 Ischaemic heart disease may be worsened by high dose inhaled I agonists,27 and, though no direct association has been shown between sudden death and high dose I3 agonists, the possibility that arrhythmias or myocardial infarction might be precipitated warrants caution in patients with ischaemic heart disease. The third worry is that tolerance might occur in inhaled 13 agonists after prolonged high dose use; but this has not been shown in practice.17 28
With these considerations in mind, the survey of domiciliary nebuliser usage in this week's BMJ makes disturbing reading (p 1611). Using a home questionnaire, Laroche et al found that 12 of 53 patients given a nebuliser for home bronchodilator use had received no instructions on its use, and less than half of the patients had been given peak flow meters to monitor their asthma. Two thirds of the 7-15 age group were receiving only inhaled f stimulant aerosols and apparently were taking neither regular oral nor inhaled corticosteroids. The dose of salbutamol varied among patients, but many were taking up to 50 mg a day and even at this dose symptoms were not relieved in some patients. Though most said that if the nebuliser failed to relieve their symptoms they would call their general practitioner, 17% said they would take further doses of nebulised 13 stimulant and not seek help. Laroche et al suggest a series of sensible recommendations for home nebuliser treatment, but these concentrate on occasional symptomatic use and fail to include the recommendations for long term nebulisation.
Our unit has adopted strict guidelines for the use of nebulisers. We urge our hospital colleagues and local general practitioners to refer patients to our clinic for full assessment before consideration of nebuliser treatment. Many patients are not using pressurised inhalers correctly when first seen,29
